Print

Donated Remdesivir Ineligible for Separate Reimbursement

June 17, 2020
Updated July 2, 2020


Gilead Sciences, Inc., announced it will start charging hospitals for remdesivir in July 2020. We will assess this change in Gilead’s payment position and the impact it may have on the availability and use of this investigational therapy. Further details on any change in our approach to the coverage and reimbursement of remdesivir for the treatment of COVID-19 will be reported here.



Facilities receiving donated remdesivir should not separately bill for the product


We continue to provide coverage for medically necessary care for the treatment of COVID-19. The federal government is currently donating remdesivir to facilities for COVID-19 treatment. Remdesivir has been granted emergency use authorization1 from the U.S. Food and Drug Administration Learn more about third-party links for the treatment of COVID-19. However, it is still considered investigational. If providers submit claims for reimbursement for donated remdesivir, we will deny it as not covered. Other medically necessary treatment associated with hospitalization for COVID-19 will be covered.


Remedsivir Donations
Gilead Sciences, Inc., the maker of remdesivir, donated the medication2 Learn more about third-party links for treatment of COVID-19. The federal government is distributing remdesivir to facilities at no charge. The donation is part of a unique federal program to assess the drug’s effectiveness in treating hospitalized COVID-19 patients.


Medical Policy Related to Remdesivir
Our Off-Label Use of Drugs Without a Medical Policy indicates that use of a drug that is experimental, investigational and unproven for an indication is considered off-label and not covered. At this time, remdesivir is considered experimental, investigational and unproven for the treatment of COVID-19 and will not be reimbursable.


1 Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment Learn more about third-party links
2 HHS announces shipments of donated remdesivir for hospitalized patients with COVID-19, May 19, 2020 Learn more about third-party links

© 2020 Gilead Sciences, Inc. All rights reserved.

CPT copyright 2019 American Medical Association (AMA). All rights reserved. CPT is a registered trademark of the AMA

Learn more about third-party links By clicking this link, you will go to a new website/app (“site”). This new site may be offered by a vendor or an independent third party. The site may also contain non-Medicare related information. In addition, some sites may require you to agree to their terms of use and privacy policy